infigratinib

Overview

Selective FGFR1/2/3 tyrosine kinase inhibitor referenced as a comparator FGFR-targeted agent in urothelial carcinoma (PMID:37682528).

Evidence in the corpus

  • Referenced in the MSK FGFR3-altered urothelial carcinoma study as the context for a prior cfDNA-based resistance study in urothelial carcinoma treated with FGFR inhibitors; motivates the serial cfDNA profiling approach applied here to erdafitinib (PMID:37682528).
  • In a PDTO functional screen of 92 sarcoma specimens, SARC0133 (RMS) was the top responder to infigratinib; WGS revealed an FGFR1 gain on chromosome 8, but PDTOs were not sensitive to dovitinib, demonstrating intra-class drug differentiation among FGFR inhibitors PMID:39305899.
  • FGFR2 fusion/rearrangement-positive iCCA: phase III trial was negative vs. gemcitabine + cisplatin but showed consistent 37.9% ORR; secondary on-target FGFR2 kinase-domain resistance mutations (N550, V565) emerge in ~60% of patients on reversible inhibitors PMID:25526346

Resistance mechanisms

  • Not directly characterized in the corpus; cross-resistance via FGFR3 gatekeeper mutations is anticipated given shared binding mode with other pan-FGFR TKIs (PMID:37682528).

Cancer types (linked)

  • BLCA
  • UTUC
  • RMS — rhabdomyosarcoma; FGFR1-gain-driven PDTO response

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:25526346

This page was processed by crosslinker on 2026-05-14.